NM_000742.4:c.1465-21T>C

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_000742.4(CHRNA2):​c.1465-21T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.311 in 1,613,550 control chromosomes in the GnomAD database, including 80,319 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.27 ( 6435 hom., cov: 33)
Exomes 𝑓: 0.31 ( 73884 hom. )

Consequence

CHRNA2
NM_000742.4 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: -0.240

Publications

11 publications found
Variant links:
Genes affected
CHRNA2 (HGNC:1956): (cholinergic receptor nicotinic alpha 2 subunit) Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels formed by a pentameric arrangement of alpha and beta subunits to create distinct muscle and neuronal receptors. Neuronal receptors are found throughout the peripheral and central nervous system where they are involved in fast synaptic transmission. This gene encodes an alpha subunit that is widely expressed in the brain. The proposed structure for nAChR subunits is a conserved N-terminal extracellular domain followed by three conserved transmembrane domains, a variable cytoplasmic loop, a fourth conserved transmembrane domain, and a short C-terminal extracellular region. Mutations in this gene cause autosomal dominant nocturnal frontal lobe epilepsy type 4. Single nucleotide polymorphisms (SNPs) in this gene have been associated with nicotine dependence. [provided by RefSeq, Nov 2009]
CHRNA2 Gene-Disease associations (from GenCC):
  • autosomal dominant nocturnal frontal lobe epilepsy 4
    Inheritance: AD Classification: STRONG, LIMITED Submitted by: G2P, Illumina, Labcorp Genetics (formerly Invitae)
  • autosomal dominant nocturnal frontal lobe epilepsy
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • familial sleep-related hypermotor epilepsy
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen
  • benign familial infantile epilepsy
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BP6
Variant 8-27461775-A-G is Benign according to our data. Variant chr8-27461775-A-G is described in ClinVar as Benign. ClinVar VariationId is 670848.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.325 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CHRNA2NM_000742.4 linkc.1465-21T>C intron_variant Intron 6 of 6 ENST00000407991.3 NP_000733.2 Q15822-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CHRNA2ENST00000407991.3 linkc.1465-21T>C intron_variant Intron 6 of 6 5 NM_000742.4 ENSP00000385026.1 Q15822-1

Frequencies

GnomAD3 genomes
AF:
0.272
AC:
41334
AN:
152086
Hom.:
6429
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.128
Gnomad AMI
AF:
0.214
Gnomad AMR
AF:
0.329
Gnomad ASJ
AF:
0.382
Gnomad EAS
AF:
0.240
Gnomad SAS
AF:
0.256
Gnomad FIN
AF:
0.376
Gnomad MID
AF:
0.361
Gnomad NFE
AF:
0.328
Gnomad OTH
AF:
0.294
GnomAD2 exomes
AF:
0.310
AC:
77683
AN:
250436
AF XY:
0.310
show subpopulations
Gnomad AFR exome
AF:
0.126
Gnomad AMR exome
AF:
0.359
Gnomad ASJ exome
AF:
0.366
Gnomad EAS exome
AF:
0.230
Gnomad FIN exome
AF:
0.372
Gnomad NFE exome
AF:
0.334
Gnomad OTH exome
AF:
0.332
GnomAD4 exome
AF:
0.315
AC:
459696
AN:
1461346
Hom.:
73884
Cov.:
35
AF XY:
0.314
AC XY:
228139
AN XY:
726984
show subpopulations
African (AFR)
AF:
0.124
AC:
4150
AN:
33472
American (AMR)
AF:
0.351
AC:
15709
AN:
44714
Ashkenazi Jewish (ASJ)
AF:
0.367
AC:
9602
AN:
26132
East Asian (EAS)
AF:
0.293
AC:
11614
AN:
39688
South Asian (SAS)
AF:
0.247
AC:
21286
AN:
86246
European-Finnish (FIN)
AF:
0.372
AC:
19874
AN:
53360
Middle Eastern (MID)
AF:
0.352
AC:
2025
AN:
5756
European-Non Finnish (NFE)
AF:
0.321
AC:
357073
AN:
1111624
Other (OTH)
AF:
0.304
AC:
18363
AN:
60354
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.473
Heterozygous variant carriers
0
16997
33994
50992
67989
84986
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
11412
22824
34236
45648
57060
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.272
AC:
41357
AN:
152204
Hom.:
6435
Cov.:
33
AF XY:
0.274
AC XY:
20412
AN XY:
74412
show subpopulations
African (AFR)
AF:
0.128
AC:
5307
AN:
41546
American (AMR)
AF:
0.329
AC:
5035
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
0.382
AC:
1327
AN:
3470
East Asian (EAS)
AF:
0.241
AC:
1247
AN:
5182
South Asian (SAS)
AF:
0.256
AC:
1236
AN:
4820
European-Finnish (FIN)
AF:
0.376
AC:
3981
AN:
10600
Middle Eastern (MID)
AF:
0.364
AC:
107
AN:
294
European-Non Finnish (NFE)
AF:
0.328
AC:
22310
AN:
67972
Other (OTH)
AF:
0.290
AC:
612
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1533
3066
4598
6131
7664
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
426
852
1278
1704
2130
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.318
Hom.:
10613
Bravo
AF:
0.262
Asia WGS
AF:
0.224
AC:
779
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
Jun 14, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

not specified Benign:1
Jul 15, 2024
Unidad de Genómica Garrahan, Hospital de Pediatría Garrahan
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is classified as Benign based on local population frequency. This variant was detected in 62% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 58. Only high quality variants are reported. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.84
CADD
Benign
2.6
DANN
Benign
0.71
PhyloP100
-0.24
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs735421; hg19: chr8-27319292; COSMIC: COSV53558381; COSMIC: COSV53558381; API